Several studies in the past few years have suggested that CD147 is associated with the progression of tumor development and cisplatin-based chemotherapy resistance of lung adenocarcinoma and may be a potential therapeutic target (Feng et al., 2017; Yang et al., 2017; Zeng et al., 2011). This evidence concerns the gene BSG and neoplasm.